<?xml version='1.0' encoding='utf-8'?>
<document id="27491280"><sentence text="Lack of a Pharmacokinetic Interaction Between Saxagliptin and Dapagliflozin in Healthy Subjects: A Randomized Crossover Study."><entity charOffset="46-57" id="DDI-PubMed.27491280.s1.e0" text="Saxagliptin" /><entity charOffset="62-75" id="DDI-PubMed.27491280.s1.e1" text="Dapagliflozin" /><pair ddi="false" e1="DDI-PubMed.27491280.s1.e0" e2="DDI-PubMed.27491280.s1.e0" /><pair ddi="false" e1="DDI-PubMed.27491280.s1.e0" e2="DDI-PubMed.27491280.s1.e1" /></sentence><sentence text="This single-dose, open-label, randomized, 3-period, 3-treatment crossover drug-drug interaction study was conducted to evaluate differences in the pharmacokinetic properties of saxagliptin and dapagliflozin when coadministered"><entity charOffset="177-188" id="DDI-PubMed.27491280.s2.e0" text="saxagliptin" /><entity charOffset="193-206" id="DDI-PubMed.27491280.s2.e1" text="dapagliflozin" /><pair ddi="false" e1="DDI-PubMed.27491280.s2.e0" e2="DDI-PubMed.27491280.s2.e0" /><pair ddi="false" e1="DDI-PubMed.27491280.s2.e0" e2="DDI-PubMed.27491280.s2.e1" /></sentence><sentence text="" /><sentence text="Healthy subjects (N = 42) were randomized to receive saxagliptin 5 mg alone, dapagliflozin 10 mg alone, or saxagliptin 5 mg plus dapagliflozin 10 mg coadministered; there was a washout period of â‰¥6 days between treatments"><entity charOffset="18-19" id="DDI-PubMed.27491280.s4.e0" text="N" /><entity charOffset="53-64" id="DDI-PubMed.27491280.s4.e1" text="saxagliptin" /><entity charOffset="77-90" id="DDI-PubMed.27491280.s4.e2" text="dapagliflozin" /><entity charOffset="107-118" id="DDI-PubMed.27491280.s4.e3" text="saxagliptin" /><entity charOffset="129-142" id="DDI-PubMed.27491280.s4.e4" text="dapagliflozin" /><pair ddi="false" e1="DDI-PubMed.27491280.s4.e0" e2="DDI-PubMed.27491280.s4.e0" /><pair ddi="false" e1="DDI-PubMed.27491280.s4.e0" e2="DDI-PubMed.27491280.s4.e1" /><pair ddi="false" e1="DDI-PubMed.27491280.s4.e0" e2="DDI-PubMed.27491280.s4.e2" /><pair ddi="false" e1="DDI-PubMed.27491280.s4.e0" e2="DDI-PubMed.27491280.s4.e3" /><pair ddi="false" e1="DDI-PubMed.27491280.s4.e0" e2="DDI-PubMed.27491280.s4.e4" /><pair ddi="false" e1="DDI-PubMed.27491280.s4.e1" e2="DDI-PubMed.27491280.s4.e1" /><pair ddi="false" e1="DDI-PubMed.27491280.s4.e1" e2="DDI-PubMed.27491280.s4.e2" /><pair ddi="false" e1="DDI-PubMed.27491280.s4.e1" e2="DDI-PubMed.27491280.s4.e3" /><pair ddi="false" e1="DDI-PubMed.27491280.s4.e1" e2="DDI-PubMed.27491280.s4.e4" /><pair ddi="false" e1="DDI-PubMed.27491280.s4.e2" e2="DDI-PubMed.27491280.s4.e2" /><pair ddi="false" e1="DDI-PubMed.27491280.s4.e2" e2="DDI-PubMed.27491280.s4.e3" /><pair ddi="false" e1="DDI-PubMed.27491280.s4.e2" e2="DDI-PubMed.27491280.s4.e4" /><pair ddi="false" e1="DDI-PubMed.27491280.s4.e3" e2="DDI-PubMed.27491280.s4.e3" /><pair ddi="false" e1="DDI-PubMed.27491280.s4.e3" e2="DDI-PubMed.27491280.s4.e4" /></sentence><sentence text=" Serial blood samples for determining saxagliptin, 5-hydroxy saxagliptin (5-OH saxagliptin; major active metabolite) and dapagliflozin plasma concentrations and pharmacokinetic parameters were collected before and up to 60 hours after the dose"><entity charOffset="38-49" id="DDI-PubMed.27491280.s5.e0" text="saxagliptin" /><entity charOffset="51-72" id="DDI-PubMed.27491280.s5.e1" text="5-hydroxy saxagliptin" /><entity charOffset="74-90" id="DDI-PubMed.27491280.s5.e2" text="5-OH saxagliptin" /><entity charOffset="121-134" id="DDI-PubMed.27491280.s5.e3" text="dapagliflozin" /><pair ddi="false" e1="DDI-PubMed.27491280.s5.e0" e2="DDI-PubMed.27491280.s5.e0" /><pair ddi="false" e1="DDI-PubMed.27491280.s5.e0" e2="DDI-PubMed.27491280.s5.e1" /><pair ddi="false" e1="DDI-PubMed.27491280.s5.e0" e2="DDI-PubMed.27491280.s5.e2" /><pair ddi="false" e1="DDI-PubMed.27491280.s5.e0" e2="DDI-PubMed.27491280.s5.e3" /><pair ddi="false" e1="DDI-PubMed.27491280.s5.e1" e2="DDI-PubMed.27491280.s5.e1" /><pair ddi="false" e1="DDI-PubMed.27491280.s5.e1" e2="DDI-PubMed.27491280.s5.e2" /><pair ddi="false" e1="DDI-PubMed.27491280.s5.e1" e2="DDI-PubMed.27491280.s5.e3" /><pair ddi="false" e1="DDI-PubMed.27491280.s5.e2" e2="DDI-PubMed.27491280.s5.e2" /><pair ddi="false" e1="DDI-PubMed.27491280.s5.e2" e2="DDI-PubMed.27491280.s5.e3" /></sentence><sentence text=" No interaction was to be concluded if the 90% CIs for the geometric mean ratios of the combination compared with each drug given alone for Cmax and AUCinf were within 0"><entity charOffset="1-13" id="DDI-PubMed.27491280.s6.e0" text="N" /></sentence><sentence text="80 to 1" /><sentence text="25" /><sentence text="" /><sentence text="The results indicated that dapagliflozin had no effect on the pharmacokinetic properties of saxagliptin, 5-OH saxagliptin, or saxagliptin total active moiety and vice versa"><entity charOffset="27-40" id="DDI-PubMed.27491280.s10.e0" text="dapagliflozin" /><entity charOffset="92-103" id="DDI-PubMed.27491280.s10.e1" text="saxagliptin" /><entity charOffset="105-121" id="DDI-PubMed.27491280.s10.e2" text="5-OH saxagliptin" /><entity charOffset="126-137" id="DDI-PubMed.27491280.s10.e3" text="saxagliptin" /><pair ddi="false" e1="DDI-PubMed.27491280.s10.e0" e2="DDI-PubMed.27491280.s10.e0" /><pair ddi="false" e1="DDI-PubMed.27491280.s10.e0" e2="DDI-PubMed.27491280.s10.e1" /><pair ddi="false" e1="DDI-PubMed.27491280.s10.e0" e2="DDI-PubMed.27491280.s10.e2" /><pair ddi="false" e1="DDI-PubMed.27491280.s10.e0" e2="DDI-PubMed.27491280.s10.e3" /><pair ddi="false" e1="DDI-PubMed.27491280.s10.e1" e2="DDI-PubMed.27491280.s10.e1" /><pair ddi="false" e1="DDI-PubMed.27491280.s10.e1" e2="DDI-PubMed.27491280.s10.e2" /><pair ddi="false" e1="DDI-PubMed.27491280.s10.e1" e2="DDI-PubMed.27491280.s10.e3" /><pair ddi="false" e1="DDI-PubMed.27491280.s10.e2" e2="DDI-PubMed.27491280.s10.e2" /><pair ddi="false" e1="DDI-PubMed.27491280.s10.e2" e2="DDI-PubMed.27491280.s10.e3" /></sentence><sentence text=" The 90% CIs for Cmax and AUCinf for all comparisons were contained entirely within the 0" /><sentence text="80 to 1" /><sentence text="25 equivalence intervals" /><sentence text=" Other pharmacokinetic parameters (apparent oral clearance or half-life) of saxagliptin or dapagliflozin were similar when each medicine was administered alone or when coadministered"><entity charOffset="76-87" id="DDI-PubMed.27491280.s14.e0" text="saxagliptin" /><entity charOffset="91-104" id="DDI-PubMed.27491280.s14.e1" text="dapagliflozin" /><pair ddi="false" e1="DDI-PubMed.27491280.s14.e0" e2="DDI-PubMed.27491280.s14.e0" /><pair ddi="false" e1="DDI-PubMed.27491280.s14.e0" e2="DDI-PubMed.27491280.s14.e1" /></sentence><sentence text=" No safety profile or tolerability findings of concern were observed during the study"><entity charOffset="1-13" id="DDI-PubMed.27491280.s15.e0" text="N" /></sentence><sentence text=" All adverse events were mild, and no serious adverse events were reported" /><sentence text="" /><sentence text="These data indicate that coadministration of saxagliptin and dapagliflozin exhibits no pharmacokinetic interaction and is well tolerated"><entity charOffset="45-56" id="DDI-PubMed.27491280.s18.e0" text="saxagliptin" /><entity charOffset="61-74" id="DDI-PubMed.27491280.s18.e1" text="dapagliflozin" /><pair ddi="false" e1="DDI-PubMed.27491280.s18.e0" e2="DDI-PubMed.27491280.s18.e0" /><pair ddi="false" e1="DDI-PubMed.27491280.s18.e0" e2="DDI-PubMed.27491280.s18.e1" /></sentence><sentence text=" ClinicalTrials" /><sentence text="gov identifier: NCT01662999"><entity charOffset="16-28" id="DDI-PubMed.27491280.s20.e0" text="N" /></sentence><sentence text="" /></document>